Wedbush initiated coverage of Eikon Therapeutics (EIKN) with an Underperform rating and $7 price target
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EIKN:
- Opening Day: SpyGlass Pharma soars in debut after strongly priced IPO
- Eikon Therapeutics completes IPO and updates governance documents
- Eikon Therapeutics opens at $17.05, IPO priced at $18.00
- Eikon Therapeutics indicated to open at $17.92, IPO priced at $18 per share
- Eikon Therapeutics 21.18M share IPO priced at $18.00